Acute promyelocytic leukemia associated with the PLZF-RARA fusion gene: two additional cases with clinical and laboratorial peculiar presentations by Rohr, Sandra S. et al.
  Universidade de São Paulo
 
2012
 
Acute promyelocytic leukemia associated with
the PLZF-RARA fusion gene: two additional
cases with clinical and laboratorial peculiar
presentations
 
 
MEDICAL ONCOLOGY, TOTOWA, v. 29, n. 4, pp. 2345-2347, DEC, 2012
http://www.producao.usp.br/handle/BDPI/42206
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Departamento de Clínica Médica - FMRP/RCM Artigos e Materiais de Revistas Científicas - FMRP/RCM
SHORT COMMUNICATION
Acute promyelocytic leukemia associated with the PLZF-RARA
fusion gene: two additional cases with clinical and laboratorial
peculiar presentations
Sandra S. Rohr • Luı´s Arthur Flores Pelloso •
Aline Borgo • Livia Chiosini De Nadai • Mihoko Yamamoto •
Eduardo M. Rego • Maria de Lourdes L. F. Chauffaille
Received: 14 December 2011 / Accepted: 17 December 2011 / Published online: 29 December 2011
 Springer Science+Business Media, LLC 2011
Abstract Acute promyelocytic leukemia (APL) is char-
acterized by the presence of the t(15;17) and PML-RARa
rearrangement, with good response to treatment with reti-
noids. However, few cases of variant APL involving
alternative chromosomal aberrations have been reported,
including t(11;17)(q23;q21) (Wells et al. in Nat Genet
17:109–113, 1; Arnould et al. in Hum Mol Genet
8:1741–1749, 2) t(5;17)(q35;q12-21), t(11;17)(q13;q21)
(Grimwade et al in Blood 96:1297–1308, 3) and der(17)
(Rego et al. in Blood (ASH Annual Meeting Abstract-
s)114:Abstract 6, 4), whereby RARa is fused to the PLZF,
NPM, NuMA, and STAT5b genes, respectively, have been
described. These cases are characterized by distinct mor-
phology, clinical presentation, and in respect to PLZF, a
lack of differentiation response to retinoids leading to the
need of different approaches concerning diagnostic meth-
ods and therapeutics. This paper describes two cases of
APL associated with the PLZF-RARA fusion gene enrolled
in the IC-APL trial that is a non-randomized, multicenter
study conducted in Brazil, Mexico, Chile and Uruguay
with the aim to improve the treatment outcome of APL
patients in developing countries. These cases, although
rare, offer a challenge to its early recognition and proper
conduction.
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Introduction
In the vast majority of patients with acute promyelocytic
leukemia (APL), the t(15;17) is detected. It leads to the
generation of the PML-RARa fusion gene, which predicts
favorable response to retinoids. However, a sizeable
minority of APL cases lack the classic t(15;17). Variant
chromosomal aberrations have been reported, including
t(11;17)(q23;q21), t(5;17)(q35;q12-21), t(11;17)(q13;q21)
[1], and der(17) [2], whereby RARa is fused to the PLZF,
NPM, NuMA, and STAT5b genes, respectively. In common
with PML-RARa-associated APL, patients with fusion
genes involving NPM and NuMA appear to be sensitive to
ATRA [1], while those with PLZF-RARa rearrangement
lack of a differentiation response to retinoids, and unfa-
vorable prognosis [3].
The IC-APL trial is a non-randomized, multicenter
study conducted in Brazil, Mexico, Chile and Uruguay
with the aim to improve the treatment outcome of APL
patients in developing countries by establishing a clinical
network that provides the conditions for the exchange of
experiences among hematologists, educational activities,
and expedite diagnosis. The treatment is based on the best
standard of care and relies on ATRA and anthracyclines for
induction and consolidation, followed by maintenance with
methotrexate, mercaptopurine, and 15-day courses of
ATRA given every 3 months. The detailed protocol is
S. S. Rohr (&)  L. A. F. Pelloso  A. Borgo 
L. C. De Nadai  M. Yamamoto 
M. de Lourdes L. F. Chauffaille
Disciplina de Hematologia e Hemoterapia, UNIFESP, Escola
Paulista de Medicina, Universidade Federal de Sa˜o Paulo, Rua
Botucatu, 740-3.andar, Sa˜o Paulo, SP CEP 04023-900, Brazil
e-mail: sandra.rohr@gmail.com
E. M. Rego
Departamento de Hematologia, Faculdade de Medicina de
Ribeira˜o Preto, Universidade de Sa˜o Paulo, Ribeira˜o Preto,
Brazil
123
Med Oncol (2012) 29:2345–2347
DOI 10.1007/s12032-011-0147-y
described elsewhere [4]. From June 2006 through Sep-
tember 2010, 215 patients with morphological suspicion of
APL were evaluated, of which 183 cases harbored the
t(15;17)/PML-RARA rearrangement, and two patients
presented variant chromosomal aberrations here described.
In the remaining 30 patients, the diagnosis of APL was
discarded.
Case 1
A 38-year-female patient complained on July 2009, of
dyspnea, chest pain, and fever. Blood tests revealed: Hb
12.6 g/dL, Ht 37.6%, VCM 87.5 fL, HCM 29.7 pg, WBC
23,600/lL (19.8% blasts), Platelets 43,000/lL with 86% of
blasts with low nuclear-cytoplasmic ratio, medium sized
with cytoplasmic granules and Auer rods, INR 1.23
(1–1.20), DHL 1583U/L (140–271), and Fibrinogen
664 mg/dL (200–400). Bone marrow aspiration showed
72% blasts with the same characteristics (Fig. 1). Immu-
nophenotyping showed positivity to: CD13 heterogeneous,
CD33 homogeneous, CD117, CD34 partial, CD4, CD65,
CD11c, CD56 partial, and negativity for CD2 and
HLA-DR. PML-RARa was negative. Marrow karyo-
type, though presenting only two metaphases, showed
46,XX,t(11,17)(q23;q22) [2]. PLZF-RARA rearrangement
was detected by Southern blot. She received all-trans ret-
inoic acid (ATRA) plus conventional chemotherapy with
daunorubicin (45 mg/m2) and cytarabine (3 ? 7). Thirty
days afterward, no remission was achieved and marrow
aspiration showed 57.6% of blasts. Reinduction with
mitoxantrone, etoposide, and cytarabine was started on
September 2009, and after recovery, marrow aspiration still
revealed 62% of blasts. She was scheduled to a third cycle
of chemotherapy but died due to sepsis with active disease.
Case 2
A 48-year-male patient presented weight loss (20 kg),
fatigue, and five episodes of tonsillitis for 3 months prior to
hospital admission on November, 2010. Blood tests
revealed: Hb 7.2 g/dL, Ht 21.4%, MCV 98.2fL, WBC
71.6 9 109/lL with 90% of blasts, medium to large size,
abundant cytoplasm, loose chromatin, no nucleolus, with
granules and Auer rods, Platelets 41 9 109/lL, and
Fibrinogen 675 mg/dL. Bone marrow aspiration was hy-
percellular 86.4% myeloid blasts (Fig. 2). Immunopheno-
typing from bone marrow blasts revealed positivity to:
CD33, CD117, CD13, CD11c, and CD11b and negativity
for CD23, CD7, CD15, CD36, CD65, CD10, CD56, CD41,
CD2, CD19, and HLA-DR. Karyotype showed no meta-
phases. PCR was positive to PLZF-RARa. The patient was
scheduled to daunorubicin (60 mg/m2) and ATRA, but no
remission was achieved. Reinduction with daunorubicin
(60 mg/m2) and cytarabine (3 ? 7) was started, partial
remission was achieved, and while waiting for the marrow
donor search, he received HIDAC and arsenic trioxide.
Allogeneic hematopoietic stem-cell transplantation is
scheduled.
Discussion
APL with PML-RARa rearrangement is described as
occurring in around 20–26.4% of AMLs in Brazil [5–7].
The variant forms involving PLZF at 11q23, NUMA1 at
11q13, NPM1 at 5q35, and STAT5B at 17q11.2 are rare,
and the two cases of PLZF-RARa here shown stands for a
frequency of 1.08% of the 185 cases enrolled in the IC-
APL, a frequency a little higher than the 0.8% described in
the worldwide literature [5]. To date, none of previous
Latin America studies estimated the frequency of APL
variants including t(11;17).Fig. 1 Case 1 peripheral blood blast cells
Fig. 2 Case 2 peripheral blood blast cells
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PLZF-RARa has been reported to have atypical APL
morphology in comparison to the classical PML-RARa,
like regular nuclei and hypo- or microgranular cells,
abundant cytoplasm, more condensed chromatin pattern in
blasts, absence of Auer rods, and increased number of
Pelgeroid neutrophils [8]. The cases here described,
although variant, did not show an atypical morphology
since they presented with granules and Auer rods.
Regarding clinical aspects, there is a tendency to
hyperleukocytosis and hemorrhagic events such as DIC in
the variant group. Both cases presented more than 23,000
white blood cells per lL, but none of them contemplated
bleeding or low fibrinogen.
From therapeutical point of view, usually t(11;17)
strongly blocks differentiation, so the PLZF-RARa variant
is characterized by poor response to retinoids as a single
agent and also to arsenic trioxide [9]. However, a number
of studies suggest that this subset of APL is not completely
resistant to differentiation approaches and may be ATRA
responsive since some differentiation response to ATRA
was observed, and complete differentiation was obtained
when cytokines or cytostatics were used in addition to RA
[10]. Despite the peculiar clinical and laboratorial presen-
tation, there was a suspicion of promyelocytic leukemia,
and patients have been treated following standardized
protocols of the IC-APL, but none of them achieved
remission.
Different from APL PML-RARa associated disease, it
seems reasonable to consider allogeneic HSCT in first CR
if a suitable donor is available in cases with t(11;17) and
that is the planning for the patient of the case 2 since a
compatible donor was found. Moreover, in a broader sense
APL t(11;17) patients to whom allo-HSCT is not feasible,
experimental approaches could be tried, but remain to be
determined.
This report shows that the APL variant form, although
rare, offers a challenge to its early recognition what can be
achieved with the combination of careful morphology
analyses, clinical presentation, and genetics tests.
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